Data from EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Low-grade serous ovarian carcinomas (LGSC) are associated with a poor response to chemotherapy and are molecularly characterized by RAS pathway activation. Using exome and whole genome sequencing, we identified recurrent mutations in the protein translational regulator EIF1AX and in NF1, USP9X, KRAS, BRAF, and NRAS. RAS pathway mutations were mutually exclusive; however, we found significant co-occurrence of mutations in NRAS and EIF1AX. Missense EIF1AX mutations were clustered at the N-terminus of the protein in a region associated with its role in ensuring translational initiation fidelity. Coexpression of mutant NRAS and EIF1AX proteins promoted proliferation and clonogenic survival in LGSC cells, providing the first example of co-occurring, growth-promoting mutational events in ovarian cancer. Cancer Res; 77(16); 4268–78. ©2017 AACR.
CITE THIS COLLECTION
FUNDING
Cancer Council New South Wales
NHMRC
Worldwide Cancer Research
Cancer Australia
U.S. Army Medical Research and Materiel Command
Cancer Council Victoria
Queensland Cancer
Cancer Council South Australia
Cancer Foundation of Western Australia
Cancer Council Tasmania
AOCS
Cancer Institute New South Wales
University of Sydney Cancer Research
Cancer Institute NSW
Westmead Medical Research Foundation
SHARE
Usage metrics
Read the peer-reviewed publication

AUTHORS (28)
- DEDariush EtemadmoghadamWAWalid J. AzarYLYing LeiTMTania MoujaberDGDale W. GarsedCKCatherine J. KennedySFSian FeredayCMChris MitchellYCYoke-Eng ChiewJHJoy HendleyRSRaghwa SharmaPHPaul R. HarnettJLJason LiECElizabeth L. ChristieAPAnn-Marie PatchJGJoshy GeorgeGAGeorge Au-YeungGMGisela Mir ArnauTHTimothy P. HollowayTSTimothy Semple